Glycemic control was slightly better with lixisenatide: mean postbaseline difference, -0.27% (95% CI: -0.32 to -0.22)
It is important to note that these benefits are based on trial data
And individuals using GLP-1 for reasons beyond weight loss, such as metabolic health optimization or inflammatory conditions, may not need full therapeutic doses
Last year, when Walmart Inc.'s US Chief Executive said drugs like Wegovy and Ozempic were causing a "slight pullback" in the number of products purchased and calories consumed, Coca-Cola and Pepsi each saw their stocks drop
Altogether, circulating GLP-1 can affect central signaling by complementary pathways, thereby supporting satiety-related signaling
1 Scientists are also studying potential links to a decreased risk of dementia as well as other neurological and behavioral benefits